Literature DB >> 27334279

Optimized polyethylenimine (PEI)-based nanoparticles for siRNA delivery, analyzed in vitro and in an ex vivo tumor tissue slice culture model.

Alexander Ewe1, Sabrina Höbel1, Claudia Heine2, Lea Merz3, Sonja Kallendrusch3, Ingo Bechmann3, Felicitas Merz3,4, Heike Franke2, Achim Aigner5.   

Abstract

The non-viral delivery of small RNA molecules like siRNAs still poses a major bottleneck for their successful application in vivo. This is particularly true with regard to crossing physiological barriers upon systemic administration. We have previously established polyethylenimine (PEI)-based complexes for therapeutic RNA formulation. These nanoplexes mediate full RNA protection against nucleolytic degradation, delivery to target tissues as well as cellular uptake, intracellular release and therapeutic efficacy in preclinical in vivo models. We herein present data on different polyplex modifications for the defined improvement of physicochemical and biological nanoparticle properties and for targeted delivery. (i) By non-covalent modifications of PEI polyplexes with phospholipid liposomes, ternary complexes ("lipopolyplexes") are obtained that combine the favorable features of PEI and lipid systems. Decreased cytotoxicity and highly efficient delivery of siRNA is achieved. Some lipopolyplexes also allow prolonged storage, thus providing formulations with higher stability. (ii) Novel tyrosine modifications of low molecular weight PEI offer further improvement of stability, biocompatibility, and knockdown efficacy of resulting nanoparticles. (iii) For ligand-mediated uptake, the shielding of surface charges is a critical requirement. This is achieved by PEI grafting with polyethylene glycol (PEG), prior to covalent coupling of anti-HER1 antibodies (Erbitux®) as ligand for targeted delivery and uptake. Beyond tumor cell culture, analyses are extended towards tumor slice cultures from tumor xenograft tissues which reflect more realistically the in vivo situation. The determination of siRNA-mediated knockdown of endogenous target genes, i.e., the oncogenic survival factor survivin and the oncogenic receptor tyrosine kinase HER2, reveals nanoparticle penetration and biological efficacy also under intact tissue and stroma conditions.

Entities:  

Keywords:  Knockdown; Lipopolyplexes; PEG-PEI-Erbitux conjugates; PEI/siRNA complexes; Polyethylenimine; RNAi; Tissue slices; siRNA

Mesh:

Substances:

Year:  2017        PMID: 27334279     DOI: 10.1007/s13346-016-0306-y

Source DB:  PubMed          Journal:  Drug Deliv Transl Res        ISSN: 2190-393X            Impact factor:   4.617


  61 in total

Review 1.  Prospects for cationic polymers in gene and oligonucleotide therapy against cancer.

Authors:  Thomas Merdan; Jindrich Kopecek; Thomas Kissel
Journal:  Adv Drug Deliv Rev       Date:  2002-09-13       Impact factor: 15.470

2.  Proton sponge trick for pH-sensitive disassembly of polyethylenimine-based siRNA delivery systems.

Authors:  Gaelle Creusat; Anne-Sophie Rinaldi; Etienne Weiss; Rkia Elbaghdadi; Jean-Serge Remy; Rita Mulherkar; Guy Zuber
Journal:  Bioconjug Chem       Date:  2010-05-19       Impact factor: 4.774

Review 3.  Non-viral vectors for gene-based therapy.

Authors:  Hao Yin; Rosemary L Kanasty; Ahmed A Eltoukhy; Arturo J Vegas; J Robert Dorkin; Daniel G Anderson
Journal:  Nat Rev Genet       Date:  2014-07-15       Impact factor: 53.242

4.  Gene delivery with low molecular weight linear polyethylenimines.

Authors:  Miriam Breunig; Uta Lungwitz; Renate Liebl; Claudia Fontanari; Juergen Klar; Armin Kurtz; Torsten Blunk; Achim Goepferich
Journal:  J Gene Med       Date:  2005-10       Impact factor: 4.565

5.  MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma.

Authors:  Ahmed Fawzy Ibrahim; Ulrike Weirauch; Maren Thomas; Arnold Grünweller; Roland K Hartmann; Achim Aigner
Journal:  Cancer Res       Date:  2011-06-20       Impact factor: 12.701

6.  Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab.

Authors:  Sabrina Höbel; Ivette Koburger; Matthias John; Frank Czubayko; Philipp Hadwiger; Hans-Peter Vornlocher; Achim Aigner
Journal:  J Gene Med       Date:  2010-03       Impact factor: 4.565

7.  Breaking up the correlation between efficacy and toxicity for nonviral gene delivery.

Authors:  Miriam Breunig; Uta Lungwitz; Renate Liebl; Achim Goepferich
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-28       Impact factor: 11.205

8.  Low-molecular-weight polyethylenimine as a non-viral vector for DNA delivery: comparison of physicochemical properties, transfection efficiency and in vivo distribution with high-molecular-weight polyethylenimine.

Authors:  Klaus Kunath; Anke von Harpe; Dagmar Fischer; Holger Petersen; Ulrich Bickel; Karlheinz Voigt; Thomas Kissel
Journal:  J Control Release       Date:  2003-04-14       Impact factor: 9.776

Review 9.  Polymeric nanoparticles for targeted drug delivery system for cancer therapy.

Authors:  Farha Masood
Journal:  Mater Sci Eng C Mater Biol Appl       Date:  2015-11-27       Impact factor: 7.328

10.  Liposomes for use in gene delivery.

Authors:  Daniel A Balazs; Wt Godbey
Journal:  J Drug Deliv       Date:  2010-12-15
View more
  9 in total

Review 1.  Nanotechnology-Assisted RNA Delivery: From Nucleic Acid Therapeutics to COVID-19 Vaccines.

Authors:  Chiara Rinoldi; Seyed Shahrooz Zargarian; Pawel Nakielski; Xiaoran Li; Anna Liguori; Francesca Petronella; Dario Presutti; Qiusheng Wang; Marco Costantini; Luciano De Sio; Chiara Gualandi; Bin Ding; Filippo Pierini
Journal:  Small Methods       Date:  2021-07-28

2.  pH-Responsive Cross-Linked Low Molecular Weight Polyethylenimine as an Efficient Gene Vector for Delivery of Plasmid DNA Encoding Anti-VEGF-shRNA for Tumor Treatment.

Authors:  Xiaoming Li; Xiaoshuang Guo; Yuan Cheng; Xiaotian Zhao; Zhiwei Fang; Yanli Luo; Shujun Xia; Yun Feng; Jianjun Chen; Wei-En Yuan
Journal:  Front Oncol       Date:  2018-09-25       Impact factor: 6.244

3.  Polymeric Nanoparticles Based on Tyrosine-Modified, Low Molecular Weight Polyethylenimines for siRNA Delivery.

Authors:  Alexander Ewe; Sandra Noske; Michael Karimov; Achim Aigner
Journal:  Pharmaceutics       Date:  2019-11-12       Impact factor: 6.321

Review 4.  Drug delivery systems for RNA therapeutics.

Authors:  Kalina Paunovska; David Loughrey; James E Dahlman
Journal:  Nat Rev Genet       Date:  2022-01-04       Impact factor: 59.581

5.  Folate-Mediated Targeted Delivery of siPLK1 by Leucine-Bearing Polyethylenimine.

Authors:  Lu Hou; Zheyu Song; Zhonghang Xu; Yuanyu Wu; Wei Shi
Journal:  Int J Nanomedicine       Date:  2020-03-02

6.  Polyethylenimine Nanoparticle-Mediated siRNA Delivery to Reduce α-Synuclein Expression in a Model of Parkinson's Disease.

Authors:  Christin Helmschrodt; Sabrina Höbel; Sandra Schöniger; Anne Bauer; Jana Bonicelli; Marieke Gringmuth; Simone A Fietz; Achim Aigner; Angelika Richter; Franziska Richter
Journal:  Mol Ther Nucleic Acids       Date:  2017-08-30

7.  Deep sequencing and automated histochemistry of human tissue slice cultures improve their usability as preclinical model for cancer research.

Authors:  Susann Haehnel; Kristin Reiche; Dennis Loeffler; Andreas Horn; Conny Blumert; Sven-Holger Puppel; Nicole Kaiser; Felicitas Rapp; Michael Rade; Friedemann Horn; Juergen Meixensberger; Ingo Bechmann; Frank Gaunitz; Karsten Winter
Journal:  Sci Rep       Date:  2019-12-27       Impact factor: 4.379

8.  Tyrosine-Modification of Polypropylenimine (PPI) and Polyethylenimine (PEI) Strongly Improves Efficacy of siRNA-Mediated Gene Knockdown.

Authors:  Sandra Noske; Michael Karimov; Achim Aigner; Alexander Ewe
Journal:  Nanomaterials (Basel)       Date:  2020-09-10       Impact factor: 5.076

9.  Efficient Treatment of Rheumatoid Arthritis by Degradable LPCE Nano-Conjugate-Delivered p65 siRNA.

Authors:  Xiaohua Chen; Bailing Zhou; Yan Gao; Kaiyu Wang; Jieping Wu; Ming Shuai; Ke Men; Xingmei Duan
Journal:  Pharmaceutics       Date:  2022-01-11       Impact factor: 6.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.